Pfizer agrees to manufacture Gilead’s coronavirus drug remdesivir

spike

A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California.

Gilead Sciences | via REUTERS

Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday. 

The multi-year agreement will support efforts to scale up the supply of the intravenous drug, which has shown to help shorten the recovery time of some hospitalized coronavirus patients, the company said. Pfizer will manufacture the drug at its McPherson, Kansas facility.

“From the beginning it was clear that no one company or

Read More

Kodak reportedly under SEC investigation over disclosure of U.S. drug producing deal

spike

The Securities and Exchange Commission is investigating Eastman Kodak’s disclosure about getting awarded a $765 million loan from the U.S. government to start producing drug ingredients, which sent the stock up on heavy volume ahead of the official announcement, the Wall Street Journal reported Tuesday.

On July 27, a day before Kodak, as well as President Donald Trump, announced the deal to produce ingredients in generic drugs in response to the coronavirus pandemic, shares of the film pioneer soared nearly 25% with trading volumes far exceeding those in previous sessions. 

The SEC’s probe, which is still at an early stage,

Read More

U.S. begins 2 trials testing Eli Lilly’s coronavirus antibody drug

spike

In this May 2020 photo provided by Eli Lilly, researchers prepare mammalian cells to produce possible COVID-19 antibodies for testing in a laboratory in Indianapolis.

David Morrison | Eli Lilly via AP

The National Institutes of Health announced Tuesday it is starting two trials testing whether an experimental antibody drug can work as a safe and effective treatment in patients with Covid-19.

The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly’s experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech AbCellera. The companies announced Monday they began a phase three trial

Read More

Eli Lilly is using mobile labs to study if its antibody drug can prevent Covid-19 in nursing homes

spike

Eli Lilly has started late-stage trials to determine whether its antibody drug can prevent Covid-19 in nursing homes — and a fleet of mobile research labs are critical to making the study possible. 

“We wanted to see if we could help people in nursing homes because the disease has been so devastating,” Dr. Dan Skovronsky, chief scientific officer of Eli Lilly, said Monday on CNBC’s “The Exchange.”  “It’s just heartbreaking to think about the isolation, the fear, the illness and death.” 

Nursing homes account for about 8% of Covid-19 cases in the U.S., but about 41% of deaths, according

Read More